{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Test+results+only&page=2",
    "query": {
      "intervention": "Test results only",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Test+results+only&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T16:48:02.318Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07632274",
      "title": "A Study to Evaluate Ibuprofen (IBU) 62.5 mg and Acetaminophen (APAP) 125 mg/5 ml in an Oral Liquid Suspension Fixed-Dose Combination Product in Children Aged 6 to 11 Years",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "Test Product",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HALEON",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "6 Years to 11 Years"
      },
      "enrollment_count": 12,
      "start_date": "2026-06-19",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-09-27T16:48:02.318Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07632274"
    },
    {
      "nct_id": "NCT06168825",
      "title": "Mind Over Matter for Black and African American Women: A Single Arm Trial Examining Feasibility and Acceptability of a Supportive Intervention",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer",
        "Breast Cancer",
        "Brain Cancer",
        "Central Nervous System Cancer",
        "Colorectal Cancer",
        "Esophageal Cancer",
        "Gynecologic Cancer",
        "Head and Neck Cancer",
        "Gastrointestinal Cancer",
        "Genitourinary Cancer",
        "Melanoma",
        "Blood Cancer",
        "Lung Cancer",
        "Acceptance and Commitment Therapy",
        "Mind-Body Therapies",
        "Psychosocial Intervention"
      ],
      "interventions": [
        {
          "name": "Mind Over Matter (MOM)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Inova Health Care Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2024-01-17",
      "completion_date": "2024-06-04",
      "has_results": false,
      "last_update_posted_date": "2025-02-27",
      "last_synced_at": "2026-09-27T16:48:02.318Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Fairfax, Virginia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06168825"
    },
    {
      "nct_id": "NCT02978508",
      "title": "Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Scabies"
      ],
      "interventions": [
        {
          "name": "Permethrin Cream, 5%",
          "type": "DRUG"
        },
        {
          "name": "Elimite",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayne Pharma International Pty Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2016-11",
      "completion_date": "2017-05",
      "has_results": true,
      "last_update_posted_date": "2020-09-02",
      "last_synced_at": "2026-09-27T16:48:02.318Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Richland, Washington",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Richland",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02978508"
    },
    {
      "nct_id": "NCT05087992",
      "title": "A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastrointestinal Cancer, Metastatic"
      ],
      "interventions": [
        {
          "name": "BI 905711",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2021-11-24",
      "completion_date": "2023-11-14",
      "has_results": true,
      "last_update_posted_date": "2025-02-19",
      "last_synced_at": "2026-09-27T16:48:02.318Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05087992"
    },
    {
      "nct_id": "NCT00483496",
      "title": "Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Solar Urticaria"
      ],
      "interventions": [
        {
          "name": "Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209)",
          "type": "DRUG"
        },
        {
          "name": "Ti02 pigmentary 3% alone (formula RV3131A-MV1211)",
          "type": "DRUG"
        },
        {
          "name": "bisoctrizole 10% alone (formula RV3131A-MV1237)",
          "type": "DRUG"
        },
        {
          "name": "Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213)",
          "type": "DRUG"
        },
        {
          "name": "Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329)",
          "type": "DRUG"
        },
        {
          "name": "Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212)",
          "type": "DRUG"
        },
        {
          "name": "Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)]",
          "type": "DRUG"
        },
        {
          "name": "V0096 CR vehicle (formula RV3131A-MV1197)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Orfagen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2007-09",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2017-12-22",
      "last_synced_at": "2026-09-27T16:48:02.318Z",
      "location_count": 2,
      "location_summary": "Detroit, Michigan • New York, New York",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00483496"
    },
    {
      "nct_id": "NCT05837455",
      "title": "NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Cancer of the Breast"
      ],
      "interventions": [
        {
          "name": "VENTANA MIB-1 Ki67 assay",
          "type": "DEVICE"
        },
        {
          "name": "Oncotype DX® Recurrence Score",
          "type": "DEVICE"
        },
        {
          "name": "PAM50-based Prosigna breast cancer gene signature assay",
          "type": "DEVICE"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Combination anthracycline and/or taxane based treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 81,
      "start_date": "2024-05-30",
      "completion_date": "2027-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-09-27T16:48:02.318Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05837455"
    },
    {
      "nct_id": "NCT00822978",
      "title": "Phase 1 Study for Safety of ACHN-490",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ACHN-490 Injection vs placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Achaogen, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 39,
      "start_date": "2009-01",
      "completion_date": "2009-10",
      "has_results": false,
      "last_update_posted_date": "2012-02-27",
      "last_synced_at": "2026-09-27T16:48:02.318Z",
      "location_count": 1,
      "location_summary": "Kalamazoo, Michigan",
      "locations": [
        {
          "city": "Kalamazoo",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00822978"
    },
    {
      "nct_id": "NCT04302025",
      "title": "A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Alectinib",
          "type": "DRUG"
        },
        {
          "name": "Entrectinib",
          "type": "DRUG"
        },
        {
          "name": "Vemurafenib",
          "type": "DRUG"
        },
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        },
        {
          "name": "Pralsetinib",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "SBRT",
          "type": "DRUG"
        },
        {
          "name": "Resection",
          "type": "PROCEDURE"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Divarasib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 99,
      "start_date": "2020-11-06",
      "completion_date": "2030-05-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-09-27T16:48:02.318Z",
      "location_count": 38,
      "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 28 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04302025"
    },
    {
      "nct_id": "NCT05833217",
      "title": "Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Long COVID",
        "Insulin Resistance",
        "Insulin Sensitivity"
      ],
      "interventions": [
        {
          "name": "Adipose Tissue Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Steady State Plasma Glucose (SSPG) Test",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 55,
      "start_date": "2023-06-06",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-12-04",
      "last_synced_at": "2026-09-27T16:48:02.318Z",
      "location_count": 2,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05833217"
    },
    {
      "nct_id": "NCT06090513",
      "title": "Molecular Services and EMR-Lab Integration Application (ELIA) for Reducing Healthcare Disparities in Cancer Patients",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Advanced Cancer",
        "Solid Tumor, Adult",
        "Myeloid Malignancy"
      ],
      "interventions": [
        {
          "name": "Comprehensive Genomic Profile testing; ELIA software; Molecular Genetic Pathologist consultation",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "limited genetic testing or no testing",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Bien-Willner Physicians Group PA",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2024-10-18",
      "completion_date": "2026-10-18",
      "has_results": false,
      "last_update_posted_date": "2024-08-06",
      "last_synced_at": "2026-09-27T16:48:02.318Z",
      "location_count": 1,
      "location_summary": "Rock Hill, South Carolina",
      "locations": [
        {
          "city": "Rock Hill",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06090513"
    }
  ]
}